Retreatment with Trastuzumab after Progression on Lapatinib-Based Therapy in Heavily Pretreated HER2-Positive Metastatic Breast Cancer: A Single-Institution Experience. Issue 6 (November 2014)

• Record Type: Journal Article
• Authors: Carli, Paolo; Militello, Loredana; Miolo, Gian Maria; Quitadamo, Daniela; Lombardi, Davide; Torrisi, Elena; Scalone, Simona; Crivellari, Diana; Spazzapan, Simon
• Is Part Of: Tumori. Volume 100:Issue 6(2014)
• Page Start: 605
• Page End: 611
• Publication Date: 2014-11
• Subjects: treatment with trastuzumab beyond progression -- trastuzumab after lapatinib -- trastuzumab and lapatinib; Cancer -- Periodicals; 616.994
• DOI: 10.1700/1778.19260
• Languages: English
• ISSNs: 0300-8916

Abstract

Aims: The study aimed to determine if retreatment with trastuzumab after progression on treatment with lapatinib is feasible in a previously heavily pretreated population of HER2-positive metastatic breast cancer patients and if some range of activity and an acceptable toxicity profile could be shown. Methods and study design: Women with HER2-positive metastatic breast carcinoma whose disease progressed after antracycline, taxane and trastuzumab-based regimens were treated at progression with lapatinib plus capecitabine. At progression on this combination, retreatment with trastuzumab combined with different cytotoxic agents was offered to most patients. The outcome of these patients was evaluated. Results: Between April 2007 and February 2013, a total of 77 patients with HER2-positive metastatic breast cancer were identified who had been treated with lapatinib plus capecitabine at our institution. At progression, 43 (55%) were treated again with a trastuzumab-based regimen, mostly gemcitabine and vinorelbine. One complete response (CR) and 17 partial responses plus 4 prolonged stable periods longer than 6 months for a 51.1% overall clinical benefit were observed. No severe toxicities were encountered except one case of heart failure reported in a heavily antracycline-pretreated patient, who, however, recovered from this toxicity. Conclusions: Even if our sample is a favorably selected population of HER2-positive patients responding to sequential targeted therapies, our data suggest that trastuzumab can be used again in association with a different cytotoxic agent in patients heavily pretreated with trastuzumab and after progression on lapatinib plus capecitabine, without any significant toxicity and with an encouraging clinical benefit rate, suggesting there is an opportunity to continue blockade of the HER2 receptor.